Content about Intensive insulinotherapy

May 22, 2012

Medical supply manufacturer BD has released a syringe with a shorter needle designed to reduce discomfort in patients with diabetes who must inject insulin, the company said Tuesday.

FRANKLIN LAKES, N.J. — Medical supply manufacturer BD has released a syringe with a shorter needle designed to reduce discomfort in patients with diabetes who must inject insulin, the company said Tuesday.

BD announced the introduction of the ultra-fine 6mm needle, saying more than 80% of patients expressed a preference for it in trials, and a recent article published by the American Association of Diabetes Educators recognized the safety and efficacy of shorter needles.

The needle is designed to deliver insulin subcutaneously in adults and children.

December 1, 2011

Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.

INDIANAPOLIS — Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.

Drug maker Eli Lilly is partnering with Brigham and Women's Hospital in Boston in a study that started in July and has enrolled 4,500 people in 17 countries to find out why many people with the disease resist a progression of insulin therapy.

July 6, 2011

Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

August 8, 2010

A company that develops healthcare and information management products has applied for a patent for...

DELRAY BEACH, Fla. A company that develops healthcare and information management products has applied for a patent for an insulin-pen tracking and recording device.

 

July 11, 2010

The Juvenile Diabetes Research Foundation has given two research grants to drug maker Biodel to...

June 9, 2010

An investigational insulin made by MannKind works at least as well in patients with Type...